Pfizer's stock is experiencing a decline today, primarily influenced by a recent analyst action. Bank of America reinstated its coverage of Pfizer with a "neutral" rating and set a price target of $29.00 per share. This rating, announced early on December 10th, reflects a cautious stance on the stock, which may have contributed to the downward pressure. Additionally, the broader analyst sentiment towards Pfizer has shown a negative shift, with a decrease in the average price target by 15.56% over the past 30 days, as reported by various analysts.
Pfizer (PFE) shares are currently trading at $25.55, down 2.13% from the previous close of $26.10, and have remained at this level since the market opened today.